+ Watch CYCC
on My Watchlist
A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.
Spike from announced review of Clinical achievements will decay as they will bleed cash through the Phase 3 trials for SEAMLESS for sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (AML), our lead indication, and they exceeded 100 patients enrolled with 37 trial sites open. The plan for 2013 seems to indicate a good list of potential drugs, but cash flow will hender the share price.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions